INmune Bio, Inc. (INMB) Misses Q2 EPS by 65c

INmune Bio, Inc. (NASDAQ: INMB) reported Q2 EPS of ($1.05), $0.65 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

You May Also Be Interested In

• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• Barclays Starts Centrus Energy Corp. (LEU) at Equalweight
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance